Agilent Technologies, considered the No. 2 manufacturer of microarrays, on Monday reported overall net earnings that represented a $250 million turnaround in the span of a year.

The company, which only months ago was instituting stringent expense management and a third round of layoffs since 2001, had net income of $104 million in its second fiscal quarter ending April 30, compared to a loss of $146 million for the same quarter in 2003. Orders across the four business groups of the Palo Alto, Calif.-based company were up some 24 percent.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.